Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates

Core Viewpoint - Krystal Biotech, Inc. reported quarterly earnings of $1.29 per share, exceeding the Zacks Consensus Estimate of $1.08 per share, and showing an increase from $0.86 per share a year ago, indicating a positive earnings surprise of +19.44% [1] Financial Performance - The company achieved revenues of $96.04 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.12%, and up from $70.28 million in the same quarter last year [2] - Over the last four quarters, Krystal Biotech has exceeded consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance and Outlook - Since the beginning of the year, Krystal Biotech shares have increased by approximately 0.2%, while the S&P 500 has gained 6.1% [3] - The company's current consensus EPS estimate for the upcoming quarter is $1.24 on revenues of $100.9 million, and for the current fiscal year, it is $5.18 on revenues of $397.35 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Krystal Biotech belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Krystal Biotech's stock performance [5]